The Efficacy of Vortioxetine on Anhedonia in Patients With Major Depressive Disorder
Abstract Background: Anhedonia is a common, persistent, and disabling phenomenon in treated adults with Major Depressive Disorder (MDD). Hitherto, relatively few
כל הפוסטים בArticle
Efficacy of vortioxetine on the physical symptoms of major depressive disorder
'מערכת אימד'
14:46
סגור לתגובות על Efficacy of vortioxetine on the physical symptoms of major depressive disorder
Abstract Background: Efficacy has been proven for vortioxetine in short-term and long-term treatment of major depressive disorder (MDD), with broad
A Network Meta-Analysis Comparing Effects of Various Antidepressant Classes on the Digit Symbol Substitution Test (DSST) as a Measure of Cognitive Dysfunction in Patients with Major Depressive Disorder
'מערכת אימד'
15:15
סגור לתגובות על A Network Meta-Analysis Comparing Effects of Various Antidepressant Classes on the Digit Symbol Substitution Test (DSST) as a Measure of Cognitive Dysfunction in Patients with Major Depressive Disorder
Abstract Major depressive disorder is a common condition that often includes cognitive dysfunction. A systematic literature review of studies and
Effectiveness of long-term vortioxetine treatment of patients with major depressive disorder
'מערכת אימד'
14:52
סגור לתגובות על Effectiveness of long-term vortioxetine treatment of patients with major depressive disorder
Abstract To investigate the effectiveness, safety, and tolerability of vortioxetine in patients treated at therapeutic doses (5–20 mg/day) for both acute and maintenance treatment, patient-level
Efficacy and tolerability of switching therapy to vortioxetine versus other antidepressants in patients with major depressive disorder
'מערכת אימד'
15:07
סגור לתגובות על Efficacy and tolerability of switching therapy to vortioxetine versus other antidepressants in patients with major depressive disorder
Abstract Objectives: To assess the relative efficacy and tolerability of vortioxetine against different antidepressant monotherapies in patients with major depressive disorder
Treatment-emergent sexual dysfunction in randomized trials of vortioxetine for major depressive disorder or generalized anxiety disorder: a pooled analysis
'מערכת אימד'
15:02
סגור לתגובות על Treatment-emergent sexual dysfunction in randomized trials of vortioxetine for major depressive disorder or generalized anxiety disorder: a pooled analysis
Abstract Objective: Antidepressants are frequently associated with treatment-emergent sexual dysfunction (TESD). Vortioxetine, which was approved for patients with major depressive disorder
The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies
'מערכת אימד'
15:10
סגור לתגובות על The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies
Abstract The safety and tolerability of vortioxetine in adults with major depressive disorder was assessed. Tolerability was based on the
Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction
'מערכת אימד'
15:05
סגור לתגובות על Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction
Abstract Introduction: Sexual dysfunction is common with serotonergic antidepressants, including selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), and
Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study
'מערכת אימד'
14:48
סגור לתגובות על Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder: results of an open-label, flexible-dose, 52-week extension study
Abstract Vortioxetine is approved for the treatment of adults with major depressive disorder. This open-label extension (OLE) study evaluated the
A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder
'מערכת אימד'
14:59
סגור לתגובות על A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder
Abstract This multicenter, randomized, double-blind, placebo-controlled, active-referenced (duloxetine 60 mg), parallel-group study evaluated the short-term efficacy and safety of vortioxetine (10–20 mg)